DekaBank Deutsche Girozentrale Buys 10,000 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Posted by Defense World Staff on Oct 15th, 2023

DekaBank Deutsche Girozentrale raised its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 100.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 10,000 shares during the period. DekaBank Deutsche Girozentrale owned about 0.11% of ANI Pharmaceuticals worth $1,061,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. State of Alaska Department of Revenue raised its stake in shares of ANI Pharmaceuticals by 9.5% during the 2nd quarter. State of Alaska Department of Revenue now owns 9,162 shares of the specialty pharmaceutical company’s stock worth $493,000 after purchasing an additional 796 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth $129,000. Rice Hall James & Associates LLC bought a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth $2,554,000. Perkins Capital Management Inc. raised its stake in shares of ANI Pharmaceuticals by 7.8% during the 2nd quarter. Perkins Capital Management Inc. now owns 9,191 shares of the specialty pharmaceutical company’s stock worth $495,000 after purchasing an additional 665 shares during the period. Finally, Teacher Retirement System of Texas bought a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth $217,000. 69.78% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on ANIP shares. Truist Financial restated a “buy” rating and issued a $70.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, August 21st. StockNews.com started coverage on ANI Pharmaceuticals in a research note on Thursday, October 5th. They issued a “hold” rating on the stock. Guggenheim restated a “buy” rating and issued a $72.00 price objective on shares of ANI Pharmaceuticals in a research note on Wednesday, September 13th. HC Wainwright lifted their target price on ANI Pharmaceuticals from $60.00 to $73.00 and gave the company a “buy” rating in a report on Tuesday, August 22nd. Finally, TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Thursday, August 10th. One analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $71.67.

Get Our Latest Stock Analysis on ANI Pharmaceuticals

Insider Transactions at ANI Pharmaceuticals

In other news, CEO Nikhil Lalwani sold 11,616 shares of the business’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $61.13, for a total transaction of $710,086.08. Following the completion of the transaction, the chief executive officer now owns 353,390 shares of the company’s stock, valued at $21,602,730.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, COO Muthusamy Shanmugam sold 9,831 shares of the business’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $51.06, for a total transaction of $501,970.86. Following the completion of the transaction, the chief operating officer now owns 1,262,789 shares of the company’s stock, valued at $64,478,006.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Nikhil Lalwani sold 11,616 shares of the business’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $61.13, for a total value of $710,086.08. Following the transaction, the chief executive officer now directly owns 353,390 shares of the company’s stock, valued at approximately $21,602,730.70. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 451,700 shares of company stock valued at $26,514,454. 28.50% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Stock Down 0.5 %

ANIP stock opened at $57.66 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.74 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $1.17 billion, a PE ratio of -120.13 and a beta of 1.06. ANI Pharmaceuticals, Inc. has a twelve month low of $32.16 and a twelve month high of $65.89. The stock has a 50-day simple moving average of $60.66 and a two-hundred day simple moving average of $51.22.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last posted its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $1.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.64. ANI Pharmaceuticals had a positive return on equity of 15.77% and a negative net margin of 1.29%. The business had revenue of $116.50 million during the quarter, compared to analyst estimates of $99.87 million. During the same quarter in the previous year, the firm earned ($0.05) EPS. The company’s quarterly revenue was up 57.6% compared to the same quarter last year. On average, equities analysts predict that ANI Pharmaceuticals, Inc. will post 3.17 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

(Free Report)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products.